Pd-L1 Assay Elisa

Description: ELISA

Description: ELISA

Description: ELISA

Description: ELISA

Description: ELISA

Description: ELISA

Description: A competitive ELISA for quantitative measurement of Canine True insulin in samples from blood, plasma, serum, cell culture supernatant and other biological fluids. This is a high quality ELISA kit developped for optimal performance with samples from the particular species.

Description: The PD-1:PD-L2 TR-FRET Assay Kit is designed to measure the inhibition of PD-1 binding to_x000D_PD-L2 in a homogeneous 384 reaction format. Cell signaling through the PD-1 receptor upon_x000D_binding the PD-L2 ligand attenuates immune responses and is exploited by both tumors and_x000D_viruses. This FRET-based assay requires no time-consuming washing steps, making it_x000D_especially suitable for high throughput screening applications. The assay procedure is_x000D_straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled_x000D_acceptor, biotin-labeled PD-L2, and an inhibitor is incubated for two hours. Then, the_x000D_fluorescence intensity is measured using a fluorescence reader.

Description: Cyclin L1 Colorimetric Cell-Based ELISA Kit

Description: This liquid Assay Medium is optimized for use with the PD-1 cell-based assay using the BPS Bioscience's PD-1/NFAT Reporter-Jurkat cell line (Cat #60535). _x000D_

Description: NCAM-L1 (Phospho-Ser1181) Colorimetric Cell-Based ELISA Kit

Description: The PD-1:PD-L2[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-L2 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on a 96-well plate. Next, PD-L2 is incubated with PD-1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

Description: The PD-L2 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L2 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L2 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Description: Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Description: Programmed cell death protein 1 (PD-1) is an inhibitory receptor that is expressed on some tumor cells and causes down regulation of the immune system by reducing T-cell activity. Anti-PD-1 monoclonal antibodies block the PD-1 receptor so the T cells are no longer inhibited and therefore activates the immune response against the tumor.

Description: How a therapeutic antibody is metabolized in the body is pertinently relevant to its efficacy. Therefore, pharmacokinetics study is an important part of the drug development. PD-1 is probably the most targeted molecule in today’s pharmaceutical industry, thanking to the clinical success of Keytruda® and Opdivo®. Many investigational anti-PD-1 mAbs are being developed. There is a growing need for a standard assay that can be used to facilitate the study of their pharmacokinetics.

Description: Cleaved-Cathepsin L1 HC (T288) Colorimetric Cell-Based ELISA Kit

Description: The PD-1/PD-L2 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of the PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_• Growth-Arrested PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing Human PD-1. These cryopreserved cells are provided in a thaw-anduse format that does not require cell propagation. These cells are modified not to be expanded and are intended to be used in a single experiment._x000D_• Expression vectors for TCR activator and Human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L2 and an engineered cell surface T cell receptor (TCR) activator.

Description: PD-L2 Rabbit Polyclonal Antibody

Description: PD-L2 Rabbit Polyclonal Antibody

Description: PD-ECGF Rabbit Polyclonal Antibody

Description: PD-ECGF Rabbit Polyclonal Antibody